Anti-Human CD2 (LO-CD2a) – Dylight® 650

Purified human T Lymphocytes

This DyLight® 650 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This DyLight® 650 conjugate is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2-8°C Wet Ice

Red Laser (652 nm)

Anti-CD2 antibody (clone LO-CD2a) activity is directed against human CD2.

Human CD2 is a 351 amino acid transmembrane glycoprotein that is part of the immunoglobulin superfamily^{1, 2}. CD2 is expressed on the surface of mature T cells, most NK cells, thymocytes, dendritic cells, and 9-12% of bone marrow cells. CD2 participates in T cell and NK cell activation and is important for thymocyte development and assembly of the immunological synapse¹. However, the role of CD2 in murine immunity is not always consistent with its function in higher animals. CD2 is known to bind to lymphocyte-associated antigen³ (CD58 and its murine analog CD48) as well as CD59.

LO-CD2a was developed as an immunosuppressive agent for use in organ allotransplantation^{3, 4}. LO-CD2a strongly inhibits mixed lymphocyte culture³ and induces T cell apoptosis⁵. Additionally, LO-CD2a induces very low levels of cytokine release, inhibits cytokine production induced by OKT3, and induces human T cell hyporesponsiveness³. The immune response is inhibited as a result of cell lysis by antibody-dependent cell mediated cytotoxicity (ADCC) induced by NK cells and activated monocytes and from CD2 down-modulation on CD2+ cells⁶. LO-CD2a also strongly inhibits proliferation of peripheral blood mononuclear cells stimulated with soluble OKT3. LO-CD2a has demonstrated immunosuppressive activity in vitro and effective T cell depletion in vivo. Unresponsiveness upon restimulation with the same antigen makes LO-CD2 distinct from other anti-CD2 antibodies⁷.

CD2 is expressed on all mature human T cells, most thymocytes, NK cells and a small proportion of bone marrow cells.

CD58 (LFA-3), CD48, CD59, CD15

1. Binder C, Cvetkovski F, Sellberg F, et al. Front Immunol. 11:1090. 2020.
2. Bierer BE, Sleckman BP, Ratnofsky SE, et al. Annu Rev Immunol. 7:579–599. 1989.
3. Latinne D, De La Parra B, Nizet Y, et al. Int Immunol. 8(7):1113-1119. 1996.
4. Bazin H, Latinne D, et al, inventors; Biotransplant Inc, assignee. LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation. US patent 6,849,258 B1. Feb 1, 2005.
5. Dumont C, Déas O, Mollereau B, et al. J Immunol. 160(8):3797-3804. 1998.
6. Nizet Y, Chentoufi AA, de la Parra B, et al. Transplantation. 69(7):1420-1428. 2000.
7. Xu Y, Kolber-Simonds D, Hope JA, et al. Clin Exp Immunol. 138(3):476-483. 2004.